KURA ONCOLOGY, INC. Available-for-sale Securities, Amortized Cost Basis
KURA ONCOLOGY, INC. (KURA) had Available-for-sale Securities, Amortized Cost Basis of $67.77 million as of 2016-09-30, per its 10-Q filed 2016-11-07.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2016-11-07
- 2016-09-30: Available-for-sale Securities, Amortized Cost Basis $67.77M.
- 2016-06-30: Available-for-sale Securities, Amortized Cost Basis $67.93M.
- 2016-03-31: Available-for-sale Securities, Amortized Cost Basis $62.13M.
- 2015-12-31: Available-for-sale Securities, Amortized Cost Basis $70.39M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2016-09-30 | $67.77M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $67.93M 10-Q · filed 2016-08-10 |
| 2016-03-31 | $62.13M 10-Q · filed 2016-05-11 |
| 2015-12-31 | $70.39M 10-Q · filed 2016-11-07 |
| 2015-09-30 | $30.02M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $26.16M 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |